THYROID TABLET

Country: Canada

Language: English

Source: Health Canada

Active ingredient:

THYROID

Available from:

SEARCHLIGHT PHARMA INC

ATC code:

H03AA05

INN (International Name):

THYROID GLAND PREPARATIONS

Dosage:

125MG

Pharmaceutical form:

TABLET

Composition:

THYROID 125MG

Administration route:

ORAL

Units in package:

500

Prescription type:

Prescription

Therapeutic area:

THYROID AGENTS

Product summary:

Active ingredient group (AIG) number: 0107351002; AHFS:

Authorization status:

APPROVED

Authorization date:

2022-10-04

Summary of Product characteristics





PRESCRIBING INFORMATION
Pr
THYROID
Desiccated Thyroid
Thyroid Tablets, C.S.D.
30, 60, 125 mg
Hypothyroidism Therapy
Searchlight Pharma Inc.
1600 Notre-Dame West, suite 312
Montreal, QC
H3J 1M1
Date of Preparation: OCT 4, 2022
Submission Control No: 267094




PRESCRIBING INFORMATION
PR THYROID
DESICCATED THYROID
THYROID TABLETS, C.S.D.
30, 60 AND 125 MG
THERAPEUTIC CLASSIFICATION
HYPOTHYROIDISM THERAPY
ACTIONS AND CLINICAL PHARMACOLOGY
The principal pharmacologic effect of exogenous thyroid hormones is to
increase the metabolic
rate of body tissues.
The normal thyroid gland contains approximately 200 µg of
levothyroxine (T4)/g of gland, and 15
µg of triiodothyronine (T3)/g. The ratio of these two hormones in the
circulation does not
represent the ratio in the thyroid gland, since about 80% of
peripheral triiodothyronine comes
from monodeiodination of the outer ring of levothyroxine. Peripheral
monodeiodination of
levothyroxine at the 5 position (inner ring) also results in the
formation of reverse
triiodothyronine (r T3), which is calorigenically inactive. These
facts would seem to advocate
levothyroxine as the treatment of choice for the hypothyroid patient
and to mitigate against the
administration of hormone combinations which while normalizing
thyroxine levels, may produce
triiodothyronine levels in the thyrotoxic range.
Triiodothyronine (T3) level is low in the fetus and newborn, in old
age, in chronic caloric
deprivation, hepatic cirrhosis, renal failure, surgical stress, and
chronic illnesses representing
what has been called the “low triiodothyronine syndrome.”
Pharmacokinetics:
Animal studies have shown that T4 is only partially absorbed from the
gastrointestinal tract. The degree of absorption is dependent on the
vehicle used for its
administration and by the character of the intestinal contents, the
intestinal flora, including
plasma protein, soluble dietary factors, all of which bind thyroid and
thereby make it unavailable
for diffusion. Only 41% is absorbed whe